About OptiNose
OptiNose is a company based in Morrisville (United States) founded in 2000 was acquired by Paratek Pharma in March 2025.. OptiNose has raised $120.5 million across 10 funding rounds from investors including Fidelity Investments, Paratek Pharma and bpcruk. The company has 132 employees as of December 31, 2023. OptiNose offers products and services including XHANCE, ONZETRA, and Xsail. OptiNose operates in a competitive market with competitors including MannKind Corp, Impel NeuroPharma, Alexza, Qnovia and Iconovo, among others.
- Headquarter Morrisville, United States
- Employees 132 as on 31 Dec, 2023
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Optinose Us, Inc.
-
Annual Revenue
$76.28 M2as on Dec 31, 2022
-
Net Profit
-
EBITDA
-
Total Equity Funding
$120.5 M (USD)
in 10 rounds
-
Latest Funding Round
$4.68 M (USD), Post-IPO
May 10, 2024
-
Investors
Fidelity Investments
& 6 more
-
Employee Count
132
as on Dec 31, 2023
-
Acquired by
Paratek Pharma
(Mar 19, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OptiNose
OptiNose offers a comprehensive portfolio of products and services, including XHANCE, ONZETRA, and Xsail. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Delivers steroid for treating nasal inflammation in ENT conditions.
Exhalation delivery system for migraine relief medication.
Nasal device for effective medication administration in allergies.
Unlock access to complete
Funding Insights of OptiNose
OptiNose has successfully raised a total of $120.5M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4.68 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Post-IPO — $4.7M
-
First Round
First Round
(07 Jun 2010)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2024 | Amount | Post-IPO - OptiNose | Valuation |
investors |
|
| Nov, 2021 | Amount | Post-IPO - OptiNose | Valuation |
investors |
|
| Aug, 2020 | Amount | Post-IPO - OptiNose | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in OptiNose
OptiNose has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Paratek Pharma and bpcruk. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed by the firm.
|
Founded Year | Domain | Location | |
|
Tech & life science focused stage agnostic VC firm investing primarily in Western Europe
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by OptiNose
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - OptiNose
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Optinose Comparisons
Competitors of OptiNose
OptiNose operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MannKind Corp, Impel NeuroPharma, Alexza, Qnovia and Iconovo, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of small-molecule drugs
|
|
| domain | founded_year | HQ Location |
Intranasal delivery technology for CNS diseases is developed.
|
|
| domain | founded_year | HQ Location |
Developer of products for the treatment of acute and intermittent conditions
|
|
| domain | founded_year | HQ Location |
Inhaled drug delivery devices are developed for pharmaceuticals.
|
|
| domain | founded_year | HQ Location |
Inhalation devices for medical applications are developed by Iconovo.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Optinose
Frequently Asked Questions about OptiNose
When was OptiNose founded?
OptiNose was founded in 2000 and raised its 1st funding round 10 years after it was founded.
Where is OptiNose located?
OptiNose is headquartered in Morrisville, United States.
Is OptiNose a funded company?
OptiNose is a funded company, having raised a total of $120.5M across 10 funding rounds to date. The company's 1st funding round was a Post-IPO of $250K, raised on Jun 07, 2010.
How many employees does OptiNose have?
As of Dec 31, 2023, the latest employee count at OptiNose is 132.
What is the annual revenue of OptiNose?
Annual revenue of OptiNose is $76.28M as on Dec 31, 2022.
What does OptiNose do?
OptiNose is a developer of smart devices for nasal drug delivery. The drug delivery devices can be used for powder and liquid formulations. Pipeline includes candidates for chronic nasal inflammatory disease, migraine and autism.
Who are the top competitors of OptiNose?
OptiNose's top competitors include MannKind Corp, Impel NeuroPharma and Qnovia.
What products or services does OptiNose offer?
OptiNose offers XHANCE, ONZETRA, and Xsail.
Who are OptiNose's investors?
OptiNose has 7 investors. Key investors include Fidelity Investments, Paratek Pharma, bpcruk, Athyrium Capital Management, and Avista Capital Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.